Form 4: Vertex Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Michel Lagarde, a director at Vertex Pharmaceuticals, acquired 2,398 stock options on May 1, 2025, exercisable until April 30, 2035.
Summary
- Michel Lagarde, a director of Vertex Pharmaceuticals, filed a Form 4 on May 5, 2025, reporting a transaction.
- On May 1, 2025, Lagarde acquired 2,398 stock options with an exercise price of $502.97.
- These options are fully vested and expire on April 30, 2035.
- Following the transaction, Lagarde directly owns 2,398 derivative securities.
Sentiment
Score: 5
Explanation: Routine disclosure of stock option grant; neutral impact.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a company (such as directors or officers) trade in the company's securities. This provides transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of stock options by a director aligns their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of stock option acquisition |
| 05/05/2025 | Date of Form 4 filing |
| 04/30/2035 | Expiration date of the stock options |
Keywords
Form 4, Stock Options, Director, VRTX, Vertex Pharmaceuticals, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.